KMTS vs PATH · rev $59.8M vs P/E 19, rev $1.61B
Kestra Medical Technologies, Ltd. Common Stock (KMTS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Kestra Medical Technologies, Ltd. Common Stock (KMTS) is a medical instruments & supplies company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported KMTS revenue for 2025-04-30 was $59.8M. Net income was -$113.8M. Revenue was up 115.1% from 2024-04-30 to 2025-04-30. KMTS currently screens at market cap $1.24B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
KMTS currently screens at market cap $1.24B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the KMTS and PATH stock pages for the full models.
Not investment advice.